Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 February 2012Website:
http://www.cocrystalpharma.comNext earnings report:
13 May 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:49:51 GMTDividend
Analysts recommendations
Institutional Ownership
COCP Latest News
BOTHELL, Wash., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc .'s (Nasdaq: COCP) management announces its participation in the upcoming Virtual Investor Summit Microcap Forum in August and the H.C. Wainwright 26th Annual Global Investment Conference in September.
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / CoCrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses and noroviruses, announces that management will present a company overview at the virtual Investor Summit Microcap Forum being held Tuesday, August 20, 2024. Management will be available for 1-on-1 meetings throughout the day.
Penny stocks to watch this week under $3. The post Penny Stocks To Buy Now?
What type of business is Cocrystal Pharma?
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
What sector is Cocrystal Pharma in?
Cocrystal Pharma is in the Healthcare sector
What industry is Cocrystal Pharma in?
Cocrystal Pharma is in the Biotechnology industry
What country is Cocrystal Pharma from?
Cocrystal Pharma is headquartered in United States
When did Cocrystal Pharma go public?
Cocrystal Pharma initial public offering (IPO) was on 22 February 2012
What is Cocrystal Pharma website?
https://www.cocrystalpharma.com
Is Cocrystal Pharma in the S&P 500?
No, Cocrystal Pharma is not included in the S&P 500 index
Is Cocrystal Pharma in the NASDAQ 100?
No, Cocrystal Pharma is not included in the NASDAQ 100 index
Is Cocrystal Pharma in the Dow Jones?
No, Cocrystal Pharma is not included in the Dow Jones index
When was Cocrystal Pharma the previous earnings report?
No data
When does Cocrystal Pharma earnings report?
The next expected earnings date for Cocrystal Pharma is 13 May 2025